Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tufts Study Reveals Mixed Results on Postmarketing Studies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tufts Study Reveals Mixed Results on Postmarketing Studies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

While the number of postmarketing studies for newly approved drugs have increased during the past six years, drug developers feel that the results offer little to their understanding of safety, efficacy, or quality, according to a recently completed assessment by the Tufts Center for the Study of Drug Development. The Tufts CSDD survey found that 68% of clinical study sponsors and 79% of nonclinical study sponsors said results contributed either marginally or not at all to their understanding of the safety, efficacy, or quality of their product. However, 32% said clinical studies significantly or very significantly increased their understanding of their products.

“A lot of progress has been made in the area of postapproval studies since 2001, when the FDA regulation requiring sponsors to provide annual reports on the status of postmarketing studies went into effect,” said Tufts CSDD associate director Christopher Paul Milne. “But a major challenge drug sponsors face is completing the studies on time.”

The study found that more than half of all postmarketing studies submitted were finished by their projected completion date, but 45% were delayed due to enrollment problems, technical difficulties, additional FDA requirements, or sponsors expanding the scope of their studies.

The Prescription Drug User Fee Act (PDUFA), which authorizes the FDA to request postmarketing study reports, is due for renewal in Congress later this year.

The analysis also found that: clinical studies took approximately 10 months longer to complete and cost nine times as much as nonclinical studies; postmarketing studies are typically the responsibility of applicable R&D departments and not marketing departments, as some PDUFA critics claim; and between 1998 and 2005 sponsors spent approximately $5.3 million per postmarketing study, compared to $610,000 per nonclinical study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics